Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
  1. Home
  2. Programs
  3. CME/CE

The Evolving Role of MET TKIs in NSCLC

4 chapters
Play All
0.75 credits
45 minutes
Chapter 1
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-Test Skip straight to the post-test if you have already participated in this activity.
Media formats available:
0.75 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details
Presenters
Related
Comments
  • Overview

    The MET pathway can be activated by MET exon 14 skipping mutations, gene amplification, or overexpression. Mutations within this pathway carry a poor prognosis for patients with non-small cell lung cancer (NSCLC). Early studies of MET tyrosine kinase inhibitors (TKIs) demonstrated limited clinical benefit; however, newer selective MET TKIs, such as capmatinib and tepotinib, have improved efficacy and acceptable safety profiles. In this activity, our experts assess the role of the role of MET gene aberrations in NSCLC and optimal testing modalities, as well as the clinical evidence supporting the use of MET TKIs and the potential role of these therapies in other subsets of disease. 

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.  

    Faculty:  

    Gilberto de Lima Lopes, Jr, MD, MBA, FASCO
    Associate Director, Global Oncology
    Sylvester Comprehensive Cancer Center
    The University of Miami
    Miami, FL 

    Dr. Lopes has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: AstraZeneca, Blueprint Medicines, Boehringer Ingelheim, Janssen Consulting, Merck, Pfizer
    Contracted Research: AstraZeneca, E.R. Squibb Sons, LLC, Lucence, Xilis 
    Other Relationship: Mirati Therapeutics
    Ownership Interests: Biomab, CDR-Life, Lucence Diagnostics, Morphometrix, Xilis 

    Jyoti D. Patel, MD, FASCO
    Associate Vice Chair, Dept. of Medicine
    Feinberg School of Medicine
    Northwestern University
    Chicago, IL 

    Dr. Patel has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: AbbVie, AstraZeneca, Eli Lilly, Genentech, Takeda 

    Reviewers/Content Planners/Authors: 

    • Cindy Davidson has nothing to disclose.
    • Wilma Guerra has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to: 

    • Identify effective testing modalities for biomarker assessment in non-small cell lung cancer (NSCLC)
    • Summarize recent NSCLC trial results and recognize how they affect current clinical practice  
    • Identify new potential indications for MET inhibitors within NSCLC, such as a combination approach for EGFR TKI resistance 
    • Integrate guidelines, patient preferences, and treatment adherence into NSCLC treatment planning strategies   
  • Target Audience

    This activity has been designed to meet the educational needs of medical oncologists, pathologists, and pulmonologists, as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with NSCLC. 

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

    The American Medical Association has an agreement of mutual recognition of continuing medical education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM  to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu. 

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .75 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity. 


    Global Learning Collaborative (GLC) designates this activity for 0.7
    5 contact hours/0.075 CEUs of pharmacy contact hours.1 
     
    The Universal Activity Number for this program is UAN JA0006235-0000-24-130-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).   

    1A CEU is one-tenth of the credits certified. For example, if 4.0 credits, the CEUs would be 0.4. 

  • Provider(s)/Educational Partner(s)

    AGILEAcademy for Global Interprofessional Learning and Education – designs, develops, and delivers education across a broad spectrum of diseases and clinical conditions. Our mission is to serve as a trusted source of clinical information that helps healthcare professionals improve competence, performance, and patient outcomes. 

  • Commercial Support

    This activity is supported by an independent educational grant from Merck KGaA, Darmstadt, Germany. 

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and AGILE. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of AGILE you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site. 

    Reproduction Prohibited
    Reproduction of this materialis not permitted without written permission from the copyright owner. 

    Disclaimer: Some products discussed in this activity may not have received regulatory approval by the US FDA for the treatment of patients. The FDA has stated that “good medical practice and the best interests of the patient require that physicians use legally available drugs, biologics and devices according to their best knowledge and judgement.” 

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Recommended
Details
Presenters
Related
Comments
  • Overview

    The MET pathway can be activated by MET exon 14 skipping mutations, gene amplification, or overexpression. Mutations within this pathway carry a poor prognosis for patients with non-small cell lung cancer (NSCLC). Early studies of MET tyrosine kinase inhibitors (TKIs) demonstrated limited clinical benefit; however, newer selective MET TKIs, such as capmatinib and tepotinib, have improved efficacy and acceptable safety profiles. In this activity, our experts assess the role of the role of MET gene aberrations in NSCLC and optimal testing modalities, as well as the clinical evidence supporting the use of MET TKIs and the potential role of these therapies in other subsets of disease. 

  • Disclosure of Relevant Financial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.  

    Faculty:  

    Gilberto de Lima Lopes, Jr, MD, MBA, FASCO
    Associate Director, Global Oncology
    Sylvester Comprehensive Cancer Center
    The University of Miami
    Miami, FL 

    Dr. Lopes has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: AstraZeneca, Blueprint Medicines, Boehringer Ingelheim, Janssen Consulting, Merck, Pfizer
    Contracted Research: AstraZeneca, E.R. Squibb Sons, LLC, Lucence, Xilis 
    Other Relationship: Mirati Therapeutics
    Ownership Interests: Biomab, CDR-Life, Lucence Diagnostics, Morphometrix, Xilis 

    Jyoti D. Patel, MD, FASCO
    Associate Vice Chair, Dept. of Medicine
    Feinberg School of Medicine
    Northwestern University
    Chicago, IL 

    Dr. Patel has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: AbbVie, AstraZeneca, Eli Lilly, Genentech, Takeda 

    Reviewers/Content Planners/Authors: 

    • Cindy Davidson has nothing to disclose.
    • Wilma Guerra has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to: 

    • Identify effective testing modalities for biomarker assessment in non-small cell lung cancer (NSCLC)
    • Summarize recent NSCLC trial results and recognize how they affect current clinical practice  
    • Identify new potential indications for MET inhibitors within NSCLC, such as a combination approach for EGFR TKI resistance 
    • Integrate guidelines, patient preferences, and treatment adherence into NSCLC treatment planning strategies   
  • Target Audience

    This activity has been designed to meet the educational needs of medical oncologists, pathologists, and pulmonologists, as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with NSCLC. 

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

    The American Medical Association has an agreement of mutual recognition of continuing medical education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM  to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu. 

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of .75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for .75 nursing contact hour. Nurses should claim only the credit commensurate with the extent of their participation in the activity. 


    Global Learning Collaborative (GLC) designates this activity for 0.7
    5 contact hours/0.075 CEUs of pharmacy contact hours.1 
     
    The Universal Activity Number for this program is UAN JA0006235-0000-24-130-H01-P. This learning activity is knowledge-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).   

    1A CEU is one-tenth of the credits certified. For example, if 4.0 credits, the CEUs would be 0.4. 

  • Provider(s)/Educational Partner(s)

    AGILEAcademy for Global Interprofessional Learning and Education – designs, develops, and delivers education across a broad spectrum of diseases and clinical conditions. Our mission is to serve as a trusted source of clinical information that helps healthcare professionals improve competence, performance, and patient outcomes. 

  • Commercial Support

    This activity is supported by an independent educational grant from Merck KGaA, Darmstadt, Germany. 

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and AGILE. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of AGILE you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site. 

    Reproduction Prohibited
    Reproduction of this materialis not permitted without written permission from the copyright owner. 

    Disclaimer: Some products discussed in this activity may not have received regulatory approval by the US FDA for the treatment of patients. The FDA has stated that “good medical practice and the best interests of the patient require that physicians use legally available drugs, biologics and devices according to their best knowledge and judgement.” 

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Schedule14 Oct 2024